| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 24, 2022 | LFCR Lifecore Biomedical, Inc. \de\ | Wynnefield Partners Small Cap Value LP I65 | 10% Owner | Buy | 250,000 | $8.09 | $2,022,500.00 | +7.1% | -17.0% | -10.3% | |
| Oct 24, 2022 | JNJ Johnson & Johnson | Fasolo Peter61 | Exec VP, Chief Hr Officer | Sell | 4,263 | $171.13 | $729,520.01 | - | -0.9% | -11.0% | |
| Oct 24, 2022 | JNJ Johnson & Johnson | Fasolo Peter61 | Exec VP, Chief Hr Officer | Sell | 20,851 | $171.19 | $3,569,558.46 | -0.4% | -0.9% | -11.0% | |
| Oct 24, 2022 | JNJ Johnson & Johnson | Fasolo Peter61 | Exec VP, Chief Hr Officer | Sell | 2,815 | $171.02 | $481,429.43 | - | -0.9% | -11.0% | |
| Oct 24, 2022 | JNJ Johnson & Johnson | Fasolo Peter61 | Exec VP, Chief Hr Officer | Sell | 8,256 | $171.14 | $1,412,940.07 | -0.2% | -0.9% | -11.0% | |
| Oct 24, 2022 | JNJ Johnson & Johnson | Fasolo Peter61 | Exec VP, Chief Hr Officer | Sell | 29,275 | $171.36 | $5,016,622.55 | -0.9% | -0.9% | -11.0% | |
| Oct 24, 2022 | JNJ Johnson & Johnson | Hait William65 | See Remarks | Sell | 15,000 | $171.55 | $2,573,220.00 | -7.9% | -0.9% | -11.0% | |
| Oct 24, 2022 | JNJ Johnson & Johnson | Fasolo Peter61 | Exec VP, Chief Hr Officer | Sell | 12,998 | $171.22 | $2,225,553.68 | -0.3% | -0.9% | -11.0% | |
| Oct 21, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 161,936 | $338.32 | $54,786,634.40 | - | +3.3% | +72.0% | |
| Oct 20, 2022 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $216.68 | $1,300,078.29 | -4.9% | +20.3% | +4.4% | |
| Oct 19, 2022 | JNJ Johnson & Johnson | Fasolo Peter61 | Exec VP, Chief Hr Officer | Sell | 29,946 | $164.50 | $4,926,206.84 | -0.6% | +5.3% | -6.9% | |
| Oct 19, 2022 | JNJ Johnson & Johnson | Fasolo Peter61 | Exec VP, Chief Hr Officer | Sell | 3,613 | $164.50 | $594,349.34 | - | +5.3% | -6.9% | |
| Oct 19, 2022 | JNJ Johnson & Johnson | Fasolo Peter61 | Exec VP, Chief Hr Officer | Sell | 22,864 | $164.50 | $3,761,196.59 | -1.3% | +5.3% | -6.9% | |
| Oct 19, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 3,547 | $335.48 | $1,189,933.37 | - | +8.9% | +79.9% | |
| Oct 19, 2022 | JNJ Johnson & Johnson | Fasolo Peter61 | Exec VP, Chief Hr Officer | Sell | 13,703 | $164.50 | $2,254,184.61 | -0.3% | +5.3% | -6.9% | |
| Oct 19, 2022 | LNTH Lantheus Holdings, Inc. | Montagut Etienne51 | Chief Business Officer | Sell | 5,860 | $72.50 | $424,874.34 | -3.5% | -23.4% | -1.9% | |
| Oct 18, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 12,042 | $334.03 | $4,022,377.18 | - | +7.1% | +81.8% | |
| Oct 18, 2022 | LNTH Lantheus Holdings, Inc. | Marshall Robert J. Jr.53 | CFO And Treasurer | Sell | 4,828 | $73.41 | $354,442.79 | -3.7% | -25.6% | -3.0% | |
| Oct 18, 2022 | ESPR Esperion Therapeutics, Inc. | Warren Eric60 | Chief Commercial Officer | Sell | 107 | $7.69 | $822.83 | -0.2% | -12.2% | -88.8% | |
| Oct 18, 2022 | ESPR Esperion Therapeutics, Inc. | Foody Joanne M.73 | Chief Medical Officer | Sell | 942 | $7.69 | $7,242.10 | -0.9% | -12.2% | -88.8% | |
| Oct 18, 2022 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 32,333 | $4.85 | $156,712.47 | -3.1% | +74.9% | +39.6% | |
| Oct 17, 2022 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 4,960 | $110.82 | $549,681.58 | -24.1% | -2.5% | +2.8% | |
| Oct 17, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 79,624 | $335.41 | $26,706,631.54 | - | +7.8% | +83.3% | |
| Oct 17, 2022 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 386 | $70.50 | $27,213.00 | -0.6% | -24.5% | +2.4% | |
| Oct 14, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 3,187 | $333.95 | $1,064,306.75 | - | +8.7% | +84.3% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.